Linked Life Data

17383282

Source:http://linkedlifedata.com/resource/pubmed/id/17383282

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-3-26
pubmed:abstractText
Patients with persistently symptomatic advanced heart failure have limited treatment options after appropriate use of standard evidence-based therapies. Current recommendations from the American College of Cardiology/American Heart Association guidelines for treatment of stage C/D heart failure beyond standard therapy include ventricular replacement, investigational agents, and palliative interventions. Given the elevated risk of this patient population, additional treatment options seem warranted. Natriuretic peptides are protean compounds that provoke vasodilation, natriuresis, neurohormonal antagonism, and reverse remodeling, but they have an uncertain risk-benefit profile affecting serum creatinine and clinical events. In the pilot, open-label FUSION I trial, the adjunctive administration of nesiritide with standard therapy for patients with advanced heart failure, was demonstrated to have a neutral effect on outcomes with no evidence of increased risk. Within a prespecified subset of high-risk patients, a potential signal of benefit on a combined end point of mortality and cardiovascular hospitalization was identified.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1097-6744
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
153
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
478-84
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design.
pubmed:affiliation
Baylor University Medical Center, Heart and Vascular Institute, Dallas, TX 75246, USA. clydey@baylorhealth.edu
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II